PubMed Health⌕ Search

PubMed · 12428548

Asthma: future directions.

Abstract

Asthma continues to be a significant health care problem, as reflected by the increasing rise in disease morbidity and mortality. Because steroids are relatively safe, clinically effective, and easy to administer, they remain the gold standard of treatment. After many decades of use, however, it is apparent that inhaled corticosteroids have failed to halt the progression of the asthma epidemic. Newer, more effective drugs are being developed to combat this disease, and the interest in developing new medications to treat allergic disease and asthma has increased exponentially. The financial burden of asthma has also been a significant motivating factor in the development of new medications. It is estimated that in 1998 the total cost of asthma on society was $11 billion [175]. This consideration has further intensified the quest to develop more effective asthma medications. Table 1 reviews the wide array of drugs currently being investigated. With the development and approval of novel asthma treatments, millions of asthma sufferers will undoubtedly have increased therapeutic options for control of their disease in the near future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Patricia Leonard, Sanjiv Sur. 2002. Asthma: future directions.. https://doi.org/10.1016/s0025-7125(02)00037-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Inappropriate use of anti-asthmatic drugs in the Italian paediatric population.

OBJECTIVE: To evaluate anti-asthmatic drug prescriptions in a large Italian paediatric population. METHODS: Prescriptions involving 417,559 children younger than 14 years old dispensed during 2000 by the retail pharmacies of 17 Italian local health units participating in the ARNO project were analysed. RESULTS: In the study, 92,890 children (22.2%) received at least one anti-asthmatic drug prescription. The prevalence of prescriptions was higher in children less than 1 year old, significantly decreased with increasing age, and was higher in boys than in girls. Of children treated with anti-asthmatic drugs, 71.5% received prescriptions of less than three boxes. Beclomethasone, salbutamol, flunisolide and fluticasone were the most prescribed drugs. Beclomethasone and flunisolide were prescribed mostly as nebulised suspension. CONCLUSIONS: The data suggest that anti-asthmatic drugs are often prescribed for diseases different from asthma and that many children are exposed to treatments for which there is no evidence of efficacy.

Anti-Asthmatic Agents↗

Recent clinical investigations examining the association of asthma and gastroesophageal reflux.

For more than a decade, investigations have examined the association between asthma and gastroesophageal reflux (GER), and have demonstrated that the presence of esophageal acid events is associated with respiratory symptoms. The most current research shows that GER is prevalent in patients with asthma, that esophageal acid may alter bronchial hyperresponsiveness, and that medical or surgical GER therapy may improve asthma outcome in selected asthma patients. Further research will build on our current knowledge base and, hopefully, enable us to better identify those patients with asthma who will most benefit from reflux therapy.

Anti-Asthmatic Agents↗